Insight Pharmaceuticals acquires Church & Dwight OTC products
LANGHORNE, Pa. Insight Pharmaceuticals on Wednesday announced the acquisition of seven brands from Church & Dwight, including Auro-Dri, an ear-drying aid; Boil Ease, a boil pain-relief product; Dermarest eczema treatment; the Gentle Naturals line of baby care products; lice treatment brand Pronto Plus; the liquid bandage Skin Shield; and the eye ointment Stye.
Financial terms were not disclosed.
The addition of the Church & Dwight brands to the Insight portfolio will strengthen its position in the OTC pharmaceuticals arena, Insight stated.
NPA criticizes remarks tying dietary supplements to tainted products
WASHINGTON The Natural Products Association on Thursday released a statement criticizing the erroneous link between legitimate dietary supplements and tainted products. “Increased scrutiny by professional sports leagues on steroid usage, which the Natural Products Association commends, has unfortunately also led to increased and unsubstantiated allegations that a ‘tainted’ or mislabeled dietary supplement is to blame when an athlete tests positive for a banned substance,” said David Seckman, NPA executive director and CEO.
“As the Dietary Supplement Health and Education Act of 1994 mandates, all ingredients must be listed on product labels and product claims must be substantiated. If this is not the case, the U.S. Food and Drug Administration—along with the Federal Trade Commission—have the authority under DSHEA to act promptly,” he said.
Seckman also noted that not all substances banned by professional sports organizations as performance enhancers are either bad or illegal. “Performance enhancers [that] are not necessarily dangerous or illegal … include caffeine, commonly used over-the-counter cold remedies and prescription medications,” he said. “Athletes have the right and responsibility to avoid their use. However, the consuming public who benefits from legitimate medications or dietary supplements – as well as a trip to the local coffee house – should not be denied their use if an athlete is unwilling or unable to follow the rules established by their sport.”
FDA hosts women’s health meeting Feb. 9
ROCKVILLE, Md. The Food and Drug Administration will be hosting a meeting on women’s health in Washington on Feb.9, according to a document slated to be published in the Federal Register on Monday.
The three-hour meeting is intended for directors of national organizations interested in discussing women’s health research and educational out reach.